Vertex Pharmaceuticals' cystic fibrosis drug, Alyftrek, gained FDA approval for patients 6 and older with certain CFTR mutations, with a January launch expected to enhance its market position.
Vertex Pharmaceuticals saw price target cuts from BMO ($520), Redburn ($550), Barclays ($418), Bernstein ($441), and Leerink ($542). The average rating is overweight, with a mean target of $507.93.